Earnings results for ASLAN PHARMACEU/ADR (NASDAQ:ASLN)
ASLAN Pharmaceuticals Limited is estimated to report earnings on 05/04/2020. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.11. The reported EPS for the same quarter last year was $-0.15.
ASLAN PHARMACEU/ADR last released its quarterly earnings data on March 19th, 2020. The reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by $0.05. ASLAN PHARMACEU/ADR has generated ($0.74) earnings per share over the last year. ASLAN PHARMACEU/ADR has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, May 4th, 2020 based off prior year’s report dates.
Analyst Opinion on ASLAN PHARMACEU/ADR (NASDAQ:ASLN)
3 Wall Street analysts have issued ratings and price targets for ASLAN PHARMACEU/ADR in the last 12 months. Their average twelve-month price target is $6.33, suggesting that the stock has a possible upside of 288.55%. The high price target for ASLN is $8.00 and the low price target for ASLN is $5.00. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus rating of “Buy.”
ASLAN PHARMACEU/ADR has received a consensus rating of Buy. The company’s average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings. According to analysts’ consensus price target of $6.33, ASLAN PHARMACEU/ADR has a potential upside of 288.5% from its current price of $1.63. ASLAN PHARMACEU/ADR has only been the subject of 1 research reports in the past 90 days.
Dividend Strength: ASLAN PHARMACEU/ADR (NASDAQ:ASLN)
ASLAN PHARMACEU/ADR does not currently pay a dividend. ASLAN PHARMACEU/ADR does not have a long track record of dividend growth.
Insiders buying/selling: ASLAN PHARMACEU/ADR (NASDAQ:ASLN)
In the past three months, ASLAN PHARMACEU/ADR insiders have not sold or bought any company stock. Only 10.28% of the stock of ASLAN PHARMACEU/ADR is held by institutions.
Earnings and Valuation of ASLAN PHARMACEU/ADR (NASDAQ:ASLN
Earnings for ASLAN PHARMACEU/ADR are expected to grow by 24.07% in the coming year, from ($0.54) to ($0.67) per share. The P/E ratio of ASLAN PHARMACEU/ADR is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of ASLAN PHARMACEU/ADR is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
More latest stories: here